NSTK · 01.2026Independent supplement reference
NutriStack
Edition 1.0Updated July 13, 2026

Pramlintide

Prescription ·Exploratory record · not publication-reviewed ·Updated July 13, 2026

Pramlintide is an FDA-approved synthetic amylin analog peptide available as prescription Symlin/SymlinPen for adjunctive use in selected people with type 1 or type 2 diabetes who use mealtime insulin. This app supports FDA-approved prescription SymlinPen products only; compounded, research-use, oral/nasal/topical, lyophilized peptide-vial, weight-loss-only, or non-prescribed amylin-analog products are unsupported.

Publication status

Exploratory record, not a reviewed medical publication.

See the editorial and medical-review policies for the publication gate.

This generated database record has not completed a claim-level review by a qualified human medical reviewer. Bibliography links and evidence labels are not approval. The page remains available for reference and is excluded from search indexing.

In short

What the research says.

A quick, data-only summary. The full evidence, dosing, and sources are below.

Pramlintide is an FDA-approved synthetic amylin analog peptide available as prescription Symlin/SymlinPen for adjunctive use in selected people with type 1 or type 2 diabetes who use mealtime insulin. NutriStack rates the supporting evidence as strong. Common adult dosing is Prescriber-directed dosing only. Symlin initiation, titration, and mealtime-insulin adjustment must follow the FDA-approved label and individualized diabetes plan; NutriStack does not provide self-directed pramlintide initiation or dose escalation., though a prescriber sets the actual dose. This profile indexes 2 sources.

What it's good for
  • Adjunctive post-meal glucose control in selected insulin-treated diabetes patients2
  • Reduces postprandial glucose excursions when used with clinician-directed insulin adjustment
  • May reduce appetite or caloric intake through amylin-mediated satiety effects
  • FDA-approved pen-injector formulation with type-specific titration instructions2
What to watch for
  • Nausea
  • Vomiting
  • Anorexia
  • Prior serious hypersensitivity reaction to pramlintide or product ingredients1
  • Hypoglycemia unawareness1

The bottom line

Evidence rating strong. Most-documented uses: adjunctive post-meal glucose control in selected insulin-treated diabetes patients, reduces postprandial glucose excursions when used with clinician-directed insulin adjustment, may reduce appetite or caloric intake through amylin-mediated satiety effects. 2 sources indexed (2026), with 0 interaction records on file.

The science

How it works, mechanistically.

Core mechanism

Pramlintide is an amylin analog that slows gastric emptying, suppresses inappropriate post-meal glucagon secretion, and promotes satiety. Because it is used with insulin, initiation changes post-meal glucose patterns and severe hypoglycemia risk.1,2

Class
Amylin Analog
Dosing

Dosing & protocol.

Common range
Prescriber-directed dosing only. Symlin initiation, titration, and mealtime-insulin adjustment must follow the FDA-approved label and individualized diabetes plan; NutriStack does not provide self-directed pramlintide initiation or dose escalation.
Recommended form
FDA-approved prescription SymlinPen pramlintide acetate injection selected by the diabetes clinician. Do not substitute compounded pramlintide, cagrilintide/CagriSema-type products, research amylin analogs, unlabeled vials, or non-prescribed products.

Subcutaneous injection before major meals as prescribed. Labeling directs abdomen or thigh injection, not arm injection, and requires pramlintide and insulin to be given as separate injections at distinct sites.2

Safety

Full safety detail.

Side effects

  • Nausea
  • Vomiting
  • Anorexia
  • Headache
  • Severe hypoglycemia when used with insulin
  • Injection-site reactions

Contraindications

  • Prior serious hypersensitivity reaction to pramlintide or product ingredients1
  • Hypoglycemia unawareness1
  • Confirmed gastroparesis1
Sources

Sources, by evidence tier.

Numbered references. Citations throughout the page link here.

Reference material

2
  • 1SYMLINPEN (pramlintide acetate) injection: prescribing informationSource linkedURLU.S. Food and Drug Administration / DailyMed · Official prescribing information and FDA drug safety communication · 2026

    Label includes boxed severe hypoglycemia warning with insulin, contraindications for serious hypersensitivity, hypoglycemia unawareness, and confirmed gastroparesis, separate-injection/no-mixing requirements, SymlinPen sharing warning, oral-medication timing, and PLLR pregnancy language.

  • 2SYMLIN (pramlintide acetate) injection: FDA SPL prescribing informationSource linkedURLU.S. Food and Drug Administration / DailyMed · Official prescribing information and FDA drug safety communication · 2026

    Official SPL view confirms mealtime-insulin dose reduction at initiation, major-meal dosing context, at least 3-day titration intervals, and pen-injector strengths.

FAQ

Common questions.

Quick answers about Pramlintide, drawn from the data on this page.

What is Pramlintide?

Pramlintide is an FDA-approved synthetic amylin analog peptide available as prescription Symlin/SymlinPen for adjunctive use in selected people with type 1 or type 2 diabetes who use mealtime insulin. This app supports FDA-approved prescription SymlinPen products only; compounded, research-use, oral/nasal/topical, lyophilized peptide-vial, weight-loss-only, or non-prescribed amylin-analog products are unsupported.

What is Pramlintide used for?

Commonly cited benefits of Pramlintide include: Adjunctive post-meal glucose control in selected insulin-treated diabetes patients; Reduces postprandial glucose excursions when used with clinician-directed insulin adjustment; May reduce appetite or caloric intake through amylin-mediated satiety effects; FDA-approved pen-injector formulation with type-specific titration instructions. NutriStack rates the overall evidence as strong.

What is a typical dose of Pramlintide?

A typical adult dose of Pramlintide is Prescriber-directed dosing only. Symlin initiation, titration, and mealtime-insulin adjustment must follow the FDA-approved label and individualized diabetes plan; NutriStack does not provide self-directed pramlintide initiation or dose escalation.. The commonly recommended form is FDA-approved prescription SymlinPen pramlintide acetate injection selected by the diabetes clinician. Do not substitute compounded pramlintide, cagrilintide/CagriSema-type products, research amylin analogs, unlabeled vials, or non-prescribed products.. These are general ranges, not personalized advice; confirm the right dose with a clinician.

What are the side effects of Pramlintide?

Reported side effects include nausea, vomiting, anorexia, headache, severe hypoglycemia when used with insulin, injection-site reactions. This is educational information; check with a healthcare professional before use.

How strong is the evidence for Pramlintide?

NutriStack rates this as Strong, meaning multiple high-quality meta-analyses or systematic reviews converge on the same finding. Full tier criteria are at https://nutristackapp.com/methodology/evidence-tiers.

Use this with your stack

Pramlintide in NutriStack.

Add it to your stack, see how it interacts with everything else you take, and get a Stack Score that updates the moment it does.

NutriStack is an informational and organizational tool, not a medical service, and not a substitute for professional advice. Always consult a qualified healthcare professional before starting, stopping, or changing any supplement or medication.